InvestorsHub Logo
Followers 231
Posts 30518
Boards Moderated 0
Alias Born 01/04/2005

Re: None

Wednesday, 08/19/2015 6:15:39 PM

Wednesday, August 19, 2015 6:15:39 PM

Post# of 427
AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody (the “Product”).

Disclaimer!
(Any post contains only my opinion as I do not make any stock recommendations. Please conduct your own due diligence. Good luck to everyone!)





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVS News